Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 33Multiple Myeloma 30Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Graft vs Host Disease 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma 24Leukemia 24Hematologic Neoplasms 20Neoplasms 18Lymphoma, Mantle-Cell 18Sarcoma 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 17Tuberous Sclerosis 15Myeloproliferative Disorders 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Burkitt Lymphoma 14Waldenstrom Macroglobulinemia 13Lymphoma, B-Cell, Marginal Zone 13Recurrence 12Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Prostatic Neoplasms 11Primary Myelofibrosis 11Melanoma 11Leukemia, Myelomonocytic, Chronic 11

Interventions

Everolimus 3Sirolimus 2dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Angiomyolipoma × Sirolimus × Clear all
NCT00126672 2022-04-25

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

Dana-Farber Cancer Institute

Phase 2 Completed
36 enrolled 8 charts

Neoplasms, Tuberous Sclerosis, Angiomyolipoma

NCT01217125 2012-03-08

Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis

Fundacio Puigvert

Phase 4 Completed
18 enrolled

Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡